Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
2018/03/28 by Tamás Constantin, Tamas Constantin, Ivan Foeldvari +26 · 26 citations
Medicine · #Ocular Diseases and Behçet’s Syndrome #Autoimmune and Inflammatory Disorders Research #Sarcoidosis and Beryllium Toxicity Research
paper · pdf · doi:10.1136/annrheumdis-2018-213131
Abstract
BACKGROUND: ingle Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and uveitis is possibly its most devastating extra-articular manifestation. Evidence-based guidelines are sparse and management is mostly based on physicians' experience. Consequently, treatment practices differ widely, within and between nations. OBJECTIVES: To provide recommendations for the diagnosis and treatment of JIA-associated uveitis. METHODS: Recommendations were developed by an evidence-informed consensus process using the European League Against Rheumatism standard operating procedures. A committee was constituted, consisting of nine experienced paediatric rheumatologists and three experts in ophthalmology from Europe. Recommendations derived from a validated systematic literature review were evaluated by an Expert Committee and subsequently discussed at two consensus meetings using nominal group techniques. Recommendations were accepted if >80% agreement was reached (including all three ophthalmologists). RESULTS: In total, 22 recommendations were accepted (with >80% agreement among experts): 3 on diagnosis, 5 on disease activity measurements, 12 on treatment and 2 on future recommendations. CONCLUSIONS: The SHARE initiative aims to identify best practices for treatment of patients suffering from JIA-associated uveitis. Within this remit, recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated by an evidence-informed consensus process to suggest a standard of care for JIA-associated uveitis patients throughout Europe.
Citations
Cited by
- Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
- Enthesitis-related arthritis: current perspectives. [europepmc]
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. [europepmc]
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. [europepmc]
- Emerging therapies in the management of macular edema: a review. [europepmc]
- Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC). [europepmc]
- Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. [europepmc]
- Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany. [europepmc]
- Efficacy and Safety of Anti-TNFα Therapy for Uveitis Associated with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. [europepmc]
- Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials. [europepmc]
- Epidemiology of pediatric uveitis and associated systemic diseases. [europepmc]
- Juvenile Idiopathic Arthritis-Associated Chronic Uveitis: Recent Therapeutic Approaches. [europepmc]
- Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER. [europepmc]
- Juvenile Idiopathic Arthritis Associated Uveitis. [europepmc]
- Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). [europepmc]
- Adalimumab in patients with vision-threatening uveitis: real-world clinical experience. [europepmc]
- Uveitis in Children and Adolescents. [europepmc]
- Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications. [europepmc]
- Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience. [europepmc]
- Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. [europepmc]
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. [europepmc]
- Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis. [europepmc]
- Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review. [europepmc]
- Systematic review of clinical practice guidelines for uveitis. [europepmc]
- An Overview of Pediatric Uveitis. [europepmc]
- JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases. [europepmc]
Related